Literature DB >> 902673

Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.

F Andreasen, E Mikkelsen.   

Abstract

After furosemide 40 mg i. v. its plasma concentration was significantly higher during an 8-hour period in 6 patients with left sided heart failure than in 8 normal subjects. The plasma clearance was significantly lower in the patients than in the normal subjects--1.23 and 2.34 ml/kg/min, respectively. The apparently smaller volume of distribution in the cardiac patients (0.140 1/kg and 0.181 1/kg, respectively) was not significantly different. In the group of normal subjects, whose ages ranged from 27 to 74 years, no correlation was found between age and either plasma clearance or volume of distribution. In all the patients, the renal clearance of furosemide rose from the first to the second hour after the injection (average +/- SD)--39 +/- 17 and 77 +/- 51 ml/min. In normal subjects, the average values did not change--116 +/- 79 and 117 +/- 54 ml/min. The urinary excretion of furosemide and a metabolite (probably a glucuronide) was measured in 16 individuals. 24-hour urines from all the subjects investigated contained between 20 and 30 mg unchanged furosemide (average 25.2 mg). In addition, between 2.7 and 11.2 mg (average 6.7 mg) furosemide was excreted as the metabolite in five patients who had been treated with furosemide for at least the preceding 6 months. An average of 0.8 +/- 0.8 mg of the metabolite was found in 11 subjects who had not previously been treated with furosemide.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902673     DOI: 10.1007/bf00561400

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Protein binding of phenprocoumon in the absence and presence of furosemide.

Authors:  L Foged; S Husted; F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-09

2.  Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure.

Authors:  F Andreasen; P Jakobsen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-07

3.  Pharmacokinetics of orally administered furosemide.

Authors:  M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

4.  [Examples of phase I: diuretics].

Authors:  W Rupp; R M Zapf
Journal:  Arzneimittelforschung       Date:  1973-11

5.  Protein binding of drugs in plasma from patients with acute renal failure.

Authors:  F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

6.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors:  P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

7.  Drug elimination and apparent volume of distribution in multicompartment systems.

Authors:  M Gibaldi; D Perrier
Journal:  J Pharm Sci       Date:  1972-06       Impact factor: 3.534

8.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

9.  Potential effect of the plasma on drug distribution.

Authors:  B K Martin
Journal:  Nature       Date:  1965-07-17       Impact factor: 49.962

10.  Intravenous administration of furosemide in heart failure.

Authors:  M Davidov; N Kakaviatos; F A Finnerty
Journal:  JAMA       Date:  1967-06-05       Impact factor: 56.272

View more
  33 in total

Review 1.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 2.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

3.  Diuretic effect and disposition of furosemide in cystic fibrosis.

Authors:  J Prandota; I J Smith; B C Hilman; J T Wilson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of frusemide.

Authors:  R E Cutler; A D Blair
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

5.  Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension.

Authors:  F Andreasen; O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

6.  Pharmacokinetics of furosemide in gestosis of pregnancy.

Authors:  E Riva; P Farina; G Tognoni; S Bottino; C Orrico; G Pardi
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

7.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

8.  Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.

Authors:  A J Scheen; J C Vancrombreucq; J Delarge; A S Luyckx
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Determinants of the diuretic response to furosemide in infants with congestive heart failure.

Authors:  T P Green; B L Mirkin
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

Review 10.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.